02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
22:41 , Jun 25, 2019 |  BC Extra  |  Financial News

June 25 Financial Quick Takes: Tasly unit planning Hong Kong IPO; plus Vesalius, Mirati and more

Tasly Biopharma looks to list in Hong Kong  Tasly Biopharmaceutical Co. Ltd. (Shanghai, China) proposed to list on the Hong Kong exchange. The company is a subsidiary of Tasly Pharmaceutical (Shanghai:600535), which holds 87.75% of...
00:43 , Jun 18, 2019 |  BC Extra  |  Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

VBI falls with HBV vaccine miss on secondary endpoint  VBI Vaccines Inc. (NASDAQ:VBIV) sank $1.24 (66%) to $0.65 Monday after reporting that two doses of Sci-B-Vac failed to show non-inferior seroprotection at day 168 vs....
22:38 , Mar 19, 2019 |  BC Extra  |  Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

The Medicines Co. (NASDAQ:MDCO) terminated the employment of Christopher Cox, EVP and chief corporate development officer, effective March 15. Details were not disclosed. Mallinckrodt plc (NYSE:MNK) hired Bryan Reasons as CFO. He will succeed interim...
20:27 , Jan 18, 2019 |  BC Week In Review  |  Clinical News

Derazantinib leads to 21% ORR in Phase II intrahepatic cholangiocarcinoma cohort

Basilea Pharmaceutica Ltd. (SIX:SLN) reported interim data from the pivotal Phase II ARQ 087-301 trial to treat intrahepatic cholangiocarcinoma showing derazantinib led to an objective response rate (ORR) of 21% and a disease control rate...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
17:21 , Jul 20, 2018 |  BC Week In Review  |  Company News

Roivant's China biotech reveals pipeline, pair of deals

Sinovant Sciences Ltd. (Shanghai, China) unveiled its pipeline, which contains four Phase III-ready assets, along with two new partnerships on July 17. Backed by Roivant Sciences GmbH (Basel, Switzerland) and Chinese private equity firm CITICPE,...
21:55 , Jul 17, 2018 |  BC Extra  |  Company News

Roivant's China biotech reveals pipeline, pair of deals

Sinovant Sciences Ltd. (Shanghai, China) unveiled its pipeline, which contains four Phase III-ready assets, along with two new partnerships on a newsy Tuesday. Backed by Roivant Sciences GmbH (Basel, Switzerland) and Chinese private equity firm...
19:56 , Jul 13, 2018 |  BC Week In Review  |  Financial News

ArQule raises $69.6M follow-on

Cancer and rare disease company ArQule Inc. (NASDAQ:ARQL) raised $69.6 million through the sale of 12.7 million shares at $5.50 in a follow-on underwritten by Leerink, Needham, Roth Capital, B. Riley FBR and JonesTrading. The...